secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2026-05-15T15:49:09+00:00
Accession:  0001193125-26-225848
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026
-------------------------------------------------------------------------------

- Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.
- Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.
- FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.
- Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.
- R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/prok-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-225848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer